MetaCap

Adlai Nortye Group (ANL) vs Apnimed (APMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 17, 2026.

Summary

Apnimed is the larger company by market cap ($739.4 million vs $710.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANL-15.15%APMD-28.96%
+33%-0%-34%
Jul 31, 20261 yearOct 16, 2026
ANL-15.15%APMD-28.96%
+30%-1%-32%
Jul 27, 20265 yearsOct 12, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANL versus APMD key metrics
MetricANLAPMD
Share price$11.03$17.76
Market cap$710.31M$739.36M
1-day change-8.77%-2.66%
YTD return+676.76%—
1-year return+572.56%—
P/E ratio (TTM)—2.46
EPS (TTM)$-0.66$7.22
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-51.87M—
52-week high$17.25$35.29
52-week low$0.879$16.12
Distance from 52-week high-36.06%-49.67%
Analyst consensusstrong_buynone
Avg. price target upside+167.45%+183.39%
Average volume212.90K533.53K
Shares outstanding58.73M41.63M
Employees10981
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Adlai Nortye Group

ANL stock →

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.

Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees

About Apnimed

APMD stock →

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.

Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees

ANL vs APMD FAQ

Which is bigger, Adlai Nortye Group or Apnimed?

Apnimed (APMD) is larger, with a market capitalization of $739.36M compared with $710.31M for Adlai Nortye Group (ANL).

Are Adlai Nortye Group and Apnimed in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons